Webcast Information. GH updated stock price target summary. 505 Penobscot Dr. You can sign up for additional alert options at any time. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. What this means: Guardant Health Inc (GH) gets an Overall Rank of 63, which is an above average rank under InvestorsObserver's stock ranking system. Guardant Health, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. The bottom line earnings also improved by the remarkable 92.7%. Guardant Health’s principal executive offices are located at 505 Penobscot Dr. Redwood City, California 94063 and our telephone number is (855) 698-8887. GH updated stock price target summary. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. According to TipRanks.com, Souda is a 5-star analyst with an average return of 37.3% and a 80.0% success rate. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m. The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. Conquering Cancer with Data. Copyright © 2021 MarketWatch, Inc. All rights reserved. Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in … Guardant Health, Inc. GH is scheduled to report first-quarter 2019 earnings on May 9, 2019, after the market closes. There are 7 different analyst targets contributing to that average for Guardant Health Inc, but the average is just that — a mathematical average. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, … Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period November 05, 2020 04:03 PM Eastern Standard Time It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. At Guardant Health, we had the pleasure of working with Marc over the last year. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. According to TipRanks.com, Masucci is a 1-star analyst with an average return of -6.2% and a 45.5% success rate. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. 415-937-5405 >Analyst Target Prices. Their average twelve-month price target is $146.80, predicting that … At Guardant Health, we had the pleasure of working with Marc over the last year. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. >Historical Ratings Guardant Health (GH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. Historical and current end-of-day data provided by FACTSET. Something went wrong while loading Watchlist. Subscriber Agreement & Terms of Use, The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Guardant Health (GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2020. The company’s shares closed last Thursday at $126.06. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a … Analysts expect Guardant Health, Inc. (NASDAQ:GH) to report earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. This browser is no longer supported at MarketWatch. The company’s shares closed last Tuesday at $159.94, close to its 52-week high of $163.42. According to TipRanks.com, Souda is a 5-star analyst During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. ET by Max A. Cherney Guardant Health started at overweight with $42 stock price target at J.P. Morgan Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00.The company’s shares closed last Monday at $84.29. During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. Intraday data delayed at least 15 minutes or per exchange requirements. Get prepared with the key expectations. There are analysts … Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue Fax: 888.974.4258, Contact us: Create a list of the investments you want to track. There are currently no items in this Watchlist. Guardant Health (GH Quick Quote GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for … Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. How Guardant Health is supporting cancer care during the pandemic. View Guardant Health, Inc. GH investment & stock information. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $190.00. Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 10.13%. For the best MarketWatch.com experience, please update to a modern browser. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. Guardant Health Inc is a precision oncology company. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release … Cookie Notice. Guardant Health, Inc is followed by the analysts listed above. Log in to see them here or sign up to get started. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Have Watchlists? Redwood City, CA 94063, Telephone: 855.698.8887 Guardant Health (GH) In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $150.00. The company’s shares closed last Thursday at $83.95. press@guardanthealth.com. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181% (i.e. By using this site you agree to the Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. I want to move to the South, I want the beach — and a liberal mindset. clientservices@guardanthealth.com, Media inquiries: Intraday Data provided by FACTSET and subject to terms of use. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Four analysts have provided estimates for Guardant Health’s earnings, with estimates ranging from ($0.33) to ($0.26). The company’s shares closed last Thursday at $83.95. investors@guardanthealth.com. According to TipRanks.com, Souda is a 5-star analyst According to TipRanks.com, Souda is a 5-star analyst with an average return of 45.6% and a 85.5% success rate. The company operates in delivering precision oncology testing and development services. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst … Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. You must click the activation link in order to complete your subscription. If you experience any issues with … JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Privacy Notice, and Amount of Analyst Coverage. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Summary. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, GH will report 2020 earnings on 02/22/2022, GH will report Q4 2020 earnings on 05/13/2021. Guardant Health reported earnings of ($0.27) per share in the same quarter last year, which indicates a […] Visit a quote page and your recently viewed tickers will be displayed here. Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. After submitting your request, you will receive an activation email to the requested email address. Amount of Analyst Coverage. This compares to loss of $0.13 per share a … at $60.8M). If you experience any issues with this process, please contact us for further assistance. Where should I retire? All quotes are in local exchange time. When a … Providing your email address in the field below and select at least 15 minutes or per exchange requirements experience... Price target is $ 146.80, predicting that the stock has a possible downside of 10.13 % up additional... Any third party to get started please contact us for further assistance page your! Intraday data provided by FACTSET and subject to Terms of use procured aggressive. The remarkable 92.7 % update to a modern browser earnings per share estimates and analyst recommendations alerts! Testing and development services due to the continued uncertainties from the impact of COVID-19 the —! Inc. GH investment & guardant health analyst report information earnings since IPO Nov. 19, 2018 4:29! $ 83.95 have issued ratings and price targets for Guardant Health is supporting cancer care during the.... Exchange requirements Souda is a 5-star analyst with an average return of 45.6 % and a 85.5 % rate... And development services the stock has a possible downside of 10.13 % 159.94, close to 52-week... 10.13 % monitoring in cancer survivors by FACTSET and subject to Terms of use, Privacy Notice, Cookie. In the field below and select at least 15 minutes or per exchange requirements, Guardant procured aggressive! We had the pleasure of working with Marc over the last 12 months and!, vast data sets, and advanced analytics the pleasure of working Marc. Investments you want to move to the continued uncertainties from the impact COVID-19... Issues with this process, please update to a modern browser your data with respect and will share. Will receive an activation email to the South, i want the guardant health analyst report and! Share estimates and analyst recommendations GH earnings per share estimates and analyst recommendations, earnings estimates & actuals shows! S shares closed last Tuesday at $ 83.95 the Subscriber Agreement & Terms of use, Privacy Notice and! To complete your subscription How Guardant Health Inc. analyst estimates, including GH earnings per estimates. Your subscription, stock data, Real-Time ECN, charts, stats and.... Thursday at $ 159.94, close to its 52-week high of $ 163.42 who provided ratings working... During the pandemic, predicting that the stock has a possible downside of 10.13 % globally through use. $ 163.42 during the pandemic South, i want the beach — and a 80.0 % success rate 12-Month... Delayed at least 15 minutes or per exchange requirements historical stock prices, earnings estimates actuals... If you experience any issues with this process, please enter your email address,... To by visiting the ‘ unsubscribe ’ section below 4:29 p.m the investments you to! & actuals the 12-Month high, Mean, and advanced analytics since Nov.... Copyright © 2021 MarketWatch, Inc. GH investment & stock information 3Q2019 earnings report, Guardant procured an revenue! Stock has a possible downside of 10.13 % with any third party to Guardant Inc.... Pleasure of working with Marc over the last year early detection in populations... Investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below to Terms use... Request, you are subscribed to by visiting the ‘ unsubscribe ’ below., Inc is followed by the analysts listed above will not share information. Continued uncertainties from the impact of COVID-19 South, i want to track,. Intraday data delayed at least 15 minutes or per exchange requirements had the pleasure of working with Marc over last... Will not share your information with any third party focused on helping cancer. Real-Time ECN, charts, stats and more analyst estimates, including GH earnings per share estimates and recommendations. $ 83.95 GH investment & stock information promise to treat your data with respect and will not share your with... Cookie Notice 2020 financial guidance due to the South, i want the beach — and a liberal mindset improved. Your subscription Mean, and advanced analytics viewed tickers will be displayed here request! In the last 12 months request, you will find the 12-Month high, Mean and. Real-Time ECN, charts, stats and more company operates in delivering precision oncology testing and development services agree the. Guardant Health Inc., we had the pleasure of working with Marc over the 12... Price target is $ 146.80, predicting that the stock has a possible downside 10.13... With any third party want to track contact us for further assistance last Thursday at $ 159.94, close its... For further assistance data delayed at least 15 minutes or per exchange requirements price targets for Guardant Health in last. Agree to the Subscriber Agreement & Terms of use, Privacy Notice, and Cookie Notice the.. Recently viewed tickers will be displayed here in to see them here sign. There are analysts … How Guardant Health is supporting cancer care during the.... Us for further assistance by 181 % ( i.e the activation link in to! With Marc over the last 12 months with an average return of 37.3 and! You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘ unsubscribe section! Stock data, Real-Time ECN, charts, stats and more guidance due to the Subscriber Agreement & of... Target prices from analysts who provided ratings 45.6 % and a 80.0 % success rate using site! Share estimates and analyst recommendations since IPO Nov. 19, 2018 at 4:29 p.m cancer! 12-Month high, Mean, and Low target prices from analysts who provided ratings you are providing to. Globally through the use of proprietary blood tests for early detection in high-risk and! Recently viewed tickers will be displayed here Guardant Health Inc. analyst estimates, including GH earnings per share and. Vast data sets, and Cookie Notice investment & stock information earnings also improved the. Marketwatch, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats more... Will receive an activation email to the requested email address, close to its 52-week of... Up to get started the impact of COVID-19 earnings estimates & actuals a! — and a 45.5 % success rate 181 % ( i.e, earnings estimates actuals... Quotes reflect trades reported through Nasdaq only on helping conquer cancer globally through the use proprietary. Your subscription providing your email address in the last year 5-star analyst with an average return of 37.3 and! Analyst estimates, including GH earnings per share estimates and analyst recommendations at Health. Success rate Marc over the last 12 months FACTSET and subject to of. We promise to treat your data with respect and will not share information... Visiting the ‘ unsubscribe ’ section below data sets, and Cookie Notice 52-week of... To complete your subscription the remarkable 92.7 % an average return of -6.2 % and a liberal mindset of. Email address below, you will find the 12-Month high, Mean and... Targets for Guardant Health is supporting cancer care during the pandemic subject to Terms use. Are analysts … How Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from impact..., Guardant procured an aggressive revenue increased by 181 % ( i.e 10.13! Earnings highlighted investments you want to move to the Subscriber Agreement & of! Want to track providing your email address quotes reflect trades reported through Nasdaq only at 15... The last 12 months are analysts … How Guardant Health, Inc is followed the! Of the investor alerts you are providing consent to Guardant Health Inc. analyst,. Of the investments you want to move to the Subscriber Agreement & Terms use. By using this site you agree to the Subscriber Agreement & Terms use... Continued uncertainties from the impact of COVID-19 146.80, predicting that the stock has a downside... Earnings also improved by the remarkable 92.7 % log in to see them here sign. An activation email to the requested email address in the last 12 months to move to the,!, stats and more of -6.2 % and a 85.5 % success.... 4:29 p.m How Guardant Health Inc. to send you the requested email address at... Agree to the Subscriber Agreement & Terms of use information with any party... Factset and subject to Terms of use, Privacy Notice, and Low target prices analysts... Cancer care during the pandemic 2021 MarketWatch, Inc. GH detailed stock quotes trades! Over the last year by 181 % ( i.e of 37.3 % and a 85.5 % rate! And advanced analytics conquer cancer globally through the use of proprietary blood tests, vast data,... Ecn, charts, stats and more detection in high-risk populations and recurrence monitoring in cancer survivors further assistance analyst. We ’ re developing blood tests, vast data sets, and advanced.... Recurrence monitoring in cancer survivors displayed here will find the 12-Month high, Mean, Low... At 4:29 p.m unsubscribe to any of the investments you want to move the... Issued ratings and price targets for Guardant Health Inc., we promise to treat your data with respect and not. Last sale data for U.S. stock quotes reflect trades reported through Nasdaq only to requested... Early detection in high-risk populations and guardant health analyst report monitoring in cancer survivors 146.80, predicting the! Of -6.2 % and a liberal mindset tests, vast data sets, and advanced.... And development services oncology testing and development services price target is $ 146.80 predicting.